FACTS ARE TAGLICH DOES NOT EVEN OWN THE STOCK. HA HA HA!! Price Target: $25.00 ON A STOCK THEY DONT EVEN OWN CURRENTLY TRADING AT $1.75.
WHAT A FRIGGIN JOKE
The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to change in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is not a market maker and does not sell to or buy from customers on a principal basis. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. Currently, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned above. Taglich Brothers, Inc., does not currently have an Investment Banking relationship with the company and was not a manager or co-manager of any offering for the company within the last three years. The company pays Taglich Brothers, Inc. a monthly fee for the creation and dissemination of research reports.
taglichbrothers.com
Hemispherx BioPharma
--------------------------------------------------------------------------------
Analyst: Andre Garnet
Taglich Rating: Speculative Buy
Price Target: $25.00
Time Horizon: 36 Months
Rating Established: January 22, 2003
Price When Established: $2.00
--------------------------------------------------------------------------------
What's New
Updated Research Report (Dated January 22, 2003)
Company Description
Hemispherx BioPharma, Inc. (HEB) is focused on the research and development of RNA drugs. The Company’s lead product, ampligen, is currently undergoing clinical trials for the treatment of chronic fatigue syndrome and HIV/AIDS and has shown extremely promising interim results.
Taglich Research Reports
Updated Research Report (Dated September 25, 2002)
Updated Research Report (Dated June 19, 2002)
Initial Research Report (Dated April 15, 2002)
--------------------------------------------------------------------------------
All Research Reports are in Adobe Acrobat format.
(for the latest Adobe Acrobat reader click here)
--------------------------------------------------------------------------------
The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to change in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is not a market maker and does not sell to or buy from customers on a principal basis. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. Currently, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned above. Taglich Brothers, Inc., does not currently have an Investment Banking relationship with the company and was not a manager or co-manager of any offering for the company within the last three years. The company pays Taglich Brothers, Inc. a monthly fee for the creation and dissemination of research reports.
Send this Page to a friend
To send this page to a friend, just fill out the form below and |
